Usefulness of traditional serum biomarkers for management of breast cancer patients

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Mirabelli, Peppino ^a   Incoronato, Mariarosaria ^a  

^a IRCCS SDN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA15 3 PROTEIN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 19 FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MOLECULAR IMAGING; NONHUMAN; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRESCRIPTION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TREATMENT RESPONSE; BLOOD; BREAST TUMOR; FEMALE; METHODOLOGY; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR IMAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890086294     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/685641     Document Type: Review

References (78)

1. Marić P., Ozretić P., Levanat S., Orešković S., Antunac K., Beketić-Orešković L., Tumor markers in breast cancer: evaluation of their clinical usefulness. Collegium Antropologicum 2011 35 1 241 247 2-s2.0-79954427170
2. Bates S. E., Clinical applications of serum tumor markers. Annals of Internal Medicine 1991 115 8 623 638 2-s2.0-0025939625
3. Plebani M., Biochemical and imaging biomarkers: the search for the Holy Grail. Clinical Chemistry and Laboratory Medicine 2010 48 8 1055 1056 2-s2.0-77955444896 10.1515/CCLM.2010.199
4. McMahon C. J., Crowley V., McCarroll N., Dunne R., Keogan M. T., Elevated tumour marker: an indication for imaging? Annals of Clinical Biochemistry 2010 47 4 327 330 2-s2.0-77954389742 10.1258/acb.2010.009235
5. Gold P., Freedman S. O., Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. The Journal of Experimental Medicine 1965 121 439 462 2-s2.0-76549177140
6. Hammarström S., The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Seminars in Cancer Biology 1999 9 2 67 81 2-s2.0-0033057177 10.1006/scbi.1998. 0119 (Pubitemid 29265523)
7. Kuespert K., Pils S., Hauck C. R., CEACAMs: their role in physiology and pathophysiology. Current Opinion in Cell Biology 2006 18 5 565 571 2-s2.0-33748310638 10.1016/j.ceb.2006.08.008 (Pubitemid 44332912)
8. Pakdel A., Naghibalhossaini F., Mokarram P., Jaberipour M., Hosseini A., Regulation of carcinoembryonic antigen release from colorectal cancer cells. Molecular Biology Reports 2012 39 4 3695 3704 2-s2.0-79959638577 10.1007/s11033-011-1144-0
9. Chan C. H. F., Stanners C. P., Recent advances in the tumour biology of the GPI-anchored carcinoembryonic antigen family members CEACAM5 and CEACAM6. Current Oncology 2007 14 2 70 73 2-s2.0-41649086438 10.3747/co.2007.109
10. Blumenthal R. D., Hansen H. J., Goldenberg D. M., Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Research 2005 65 19 8809 8817 2-s2.0-25444482609 10.1158/0008-5472.CAN-05-0420 (Pubitemid 41377369)
11. Gemei M., Mirabelli P., Di Noto R., CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo. Cancer 2013 119 4 729 738
12. Ilantzis C., Demarte L., Screaton R. A., Stanners C. P., Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia 2002 4 2 151 163 2-s2.0-0036118491 10.1038/sj/neo/7900201 (Pubitemid 34218683)
13. Duxbury M. S., Ito H., Zinner M. J., Ashley S. W., Whang E. E., CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 2004 23 2 465 473 2-s2.0-0842329842 10.1038/sj.onc.1207036 (Pubitemid 38175001)
14. Duxbury M. S., Ito H., Benoit E., Waseem T., Ashley S. W., Whang E. E., A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Research 2004 64 11 3987 3993 2-s2.0-2542535214 10.1158/0008-5472.CAN-04- 0424 (Pubitemid 38697314)
15. Chan C. H. F., Cook D., Stanners C. P., Increased colon tumor susceptibility in azoxymethane treated CEABAC transgenic mice. Carcinogenesis 2006 27 9 1909 1916 2-s2.0-33747879883 10.1093/carcin/bgl040 (Pubitemid 44288672)
16. Brayman M., Thathiah A., Carson D. D., MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reproductive Biology and Endocrinology 2004 2, article 4 2-s2.0-4344682030 10.1186/1477-7827-2-4 (Pubitemid 39130574)
17. Kufe D. W., Mucins in cancer: function, prognosis and therapy. Nature Reviews Cancer 2009 9 12 874 885 2-s2.0-70450247207 10.1038/nrc2761
18. Kufe D. W., MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 32 1073 1081
19. Ren J., Agata N., Chen D., Li Y., Yu W.-H., Huang L., Raina D., Chen W., Kharbanda S., Kufe D., Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004 5 2 163 175 2-s2.0-10744220453 10.1016/S1535-6108(04)00020-0 (Pubitemid 38283802)
20. Ren J., Bharti A., Raina D., Chen W., Ahmad R., Kufe D., MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene 2006 25 1 20 31 2-s2.0-30044445260 10.1016/j.jpain.2006.01.060 (Pubitemid 43050000)
21. Rajabi H., Alam M., Takahashi H., MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene 2013 10.1038/onc.2013.114
22. Kufe D., Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene 2010 29 42 5663 5666 2-s2.0-77958499974 10.1038/onc.2010.334
23. Tsuboi S., Tumor defense systems using O-glycans. Biological and Pharmaceutical Bullettin 2012 35 10 1633 1636
24. Suzuki Y., Sutoh M., Hatakeyama S., MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. International Journal of Oncology 2012 40 6 1831 1838
25. King C. R., Kraus M. H., Aaronson S. A., Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985 229 4717 974 976 2-s2.0-0022406444 (Pubitemid 16248488)
26. Tafe L. J., Tsongalis G. J., The human epidermal growth factor receptor 2 (HER2). Clinical Chemistry and Laboratory Medicine 2012 50 1 23 30 2-s2.0-84857826438 10.1515/CCLM.2011.707
27. Gutierrez C., Schiff R., HER2: biology, detection, and clinical implications. Archives of Pathology and Laboratory Medicine 2011 135 1 55 62 2-s2.0-79251644460
28. Wolff A. C., Hammond M. E. H., Schwartz J. N., Hagerty K. L., Alfred D. C., Cote R. J., Dowsett M., Fitzgibbons P. L., Hanna W. M., Langer A., McShane L. M., Paik S., Pegram M. D., Perez E. A., Press M. F., Rhodes A., Sturgeon C., Taube S. E., Tubbs R., Vance G. H., Van De Vijver M., Wheeler T. M., Hayes D. F., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Archives of Pathology and Laboratory Medicine 2007 131 1 18 43 2-s2.0-33846568336 (Pubitemid 46174133)
29. Karantza V., Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 2011 30 2 127 138 2-s2.0-78651397689 10.1038/onc.2010.456
30. Lehr H.-A., Folpe A., Yaziji H., Kommoss F., Gown A. M., Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. The American Journal of Clinical Pathology 2000 114 2 190 196 2-s2.0-0034525313 10.1309/CPUX-KWEH-7B26-YE19 (Pubitemid 33051866)
31. Meng Y., Wu Z., Yin X., Zhao Y., Chen M., Si Y., Yang J., Fu X., Han W., Keratin 18 attenuates estrogen receptor α -mediated signaling by sequestering LRP16 in cytoplasm. BMC Cell Biology 2009 10, article 96 2-s2.0-74549144274 10.1186/1471-2121-10-96
32. Iwaya K., Ogawa H., Mukai Y., Iwamatsu A., Mukai K., Ubiquitin- immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer. Cancer Science 2003 94 10 864 870 2-s2.0-0242525131 10.1111/j.1349-7006.2003.tb01368.x (Pubitemid 37406968)
33. Kongara S., Karantza V., The interplay between autophagy and ROS in tumorigenesis. Frontiers in Oncology 2012 171 10.3389/fonc.2012.00171
34. Kongara S., Kravchuk O., Teplova I., Lozy F., Schulte J., Moore D., Barnard N., Neumann C. A., White E., Karantza V., Autophagy regulates keratin 8 homeostasis in mammary epithelial cells and in breast tumors. Molecular Cancer Research 2010 8 6 873 884 2-s2.0-77953801711 10.1158/1541-7786.MCR-09-0494
35. Martin E. W. Jr., Kibbey W. E., DiVecchia I., Carcinoembryonic antigen. Clinical and historical aspects. Cancer 1976 37 1 62 81 2-s2.0-0017290098
36. Haagensen D. E. Jr., Kister S. J., Vandevoorde J. P., Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer 1978 42 3 1512 1519 2-s2.0-0018170630 (Pubitemid 9038285)
37. Rimsten A., Adami H. O., Wahren B., Nordin B., Carcinoembryonic antigen in serum of unselected breast-cancer patients and of non-hospitalized controls. British Journal of Cancer 1979 39 2 109 115 2-s2.0-0018409439 (Pubitemid 9132716)
38. Wang D. Y., Knyba R. E., Bulbrook R. D., Serum carcinoembryonic antigen in the diagnosis and prognosis of women with breast cancer. European Journal of Cancer and Clinical Oncology 1984 20 1 25 31 2-s2.0-0021336232 (Pubitemid 14224353)
39. Agrawal A. K., Jelen M., Rudnicki J., Grzebieniak Z., Zyśko D., Kielan W., Słonina J., Marek G., The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type. Folia Histochemica et Cytobiologica 2010 48 1 26 29 2-s2.0-77954373365 10.2478/v10042-010-0030-2
40. Park B.-W., Oh J.-W., Kim J.-H., Park S. H., Kim K.-S., Kim J. H., Lee K. S., Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Annals of Oncology 2008 19 4 675 681 2-s2.0-41549158632 10.1093/annonc/mdm538 (Pubitemid 351461037)
41. Lee J. S., Park S., Park J. M., Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Annals of Oncology 2013 24 5 1225 1312
42. Gaglia P., Caldarola B., Bussone R., Potente F., Lauro D., Jayme A., Caldarola L., Prognostic value of CEA and ferritin assay in breast cancer: a multivariate analysis. European Journal of Cancer and Clinical Oncology 1988 24 7 1151 1155 2-s2.0-0023936272
43. Duffy M. J., Serum tumor markers in breast cancer: are they of clinical value? Clinical Chemistry 2006 52 3 345 351 2-s2.0-33644544070 10.1373/clinchem.2005.059832
44. Nicolini A., Carpi A., Ferrari P., Anselmi L., Spinelli C., Conte M., Miccoli P., The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. British Journal of Cancer 2000 83 11 1412 1417 2-s2.0-0033670743
45. Liska V., Holubec L. Jr., Treska V., Vrzalova J., Skalicky T., Sutnar A., Kormunda S., Bruha J., Vycital O., Finek J., Pesta M., Pecen L., Topolcan O., Evaluation of tumour markers as differential diagnostic tool in patients with suspicion of liver metastases from breast cancer. Anticancer Research 2011 31 4 1447 1451 2-s2.0-79956082232
46. Mori S., Mori Y., Mukaiyama T., Yamada Y., Sonobe Y., Matsushita H., Sakamoto G., Akiyama T., Ogawa M., Shiraishi M., Toyoshima K., Yamamoto T., In vitro and in vivo release of soluble erbB-2 protein from human carcinoma cells. Japanese Journal of Cancer Research 1990 81 5 489 494 2-s2.0-0025281021 (Pubitemid 20207755)
47. Langton B. C., Crenshaw M. C., Chao L. A., Stuart S. G., Akita R. W., Jackson J. E., An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Research 1991 51 10 2593 2598 2-s2.0-0025860662
48. Baskić D., Ristić P., Pavlović S., Serum HER2 and CA 15-3 in breast cancer patients. Journal of BUON 2004 9 3 289 294 (Pubitemid 40360805)
49. Leyland-Jones B., Smith B. R., Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. The Lancet Oncology 2011 12 3 286 295 2-s2.0-79952035138 10.1016/S1470-2045(10)70297-7
50. Carney W. P., Neumann R., Lipton A., Leitzel K., Ali S., Price C. P., Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clinical Breast Cancer 2004 5 2 105 116 2-s2.0-3543086886 (Pubitemid 39029201)
51. Trapé J., Filella X., Alsina-Donadeu M., Juan-Pereira L., Bosch-Ferrer À., Rigo-Bonnin R., Increased plasma concentrations of tumour markers in the absence of neoplasia. Clinical Chemistry and Laboratory Medicine 2011 49 10 1605 1620 2-s2.0-80054963506 10.1515/CCLM.2011.694
52. Khatcheressian J. L., Hurley P., Bantug E., Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology 2013 31 7 961 965
53. Cardoso F., Harbeck N., Fallowfield L., Kyriakides S., Senkus E., Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012 23 supplement 7 vi11 vi19 2-s2.0-80052714639
54. ACR-SPR Practice guideline for performing FDG-PET/CT in oncology. 2012, http://www.acr.org/guidelines/
55. Boellaard R., O'Doherty M. J., Weber W. A., Mottaghy F. M., Lonsdale M. N., Stroobants S. G., Oyen W. J. G., Kotzerke J., Hoekstra O. S., Pruim J., Marsden P. K., Tatsch K., Hoekstra C. J., Visser E. P., Arends B., Verzijlbergen F. J., Zijlstra J. M., Comans E. F. I., Lammertsma A. A., Paans A. M., Willemsen A. T., Beyer T., Bockisch A., Schaefer-Prokop C., Delbeke D., Baum R. P., Chiti A., Krause B. J., FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging 2010 37 1 181 200 2-s2.0-72949107608 10.1007/s00259-009-1297-4
56. Sturgeon C. M., Duffy M. J., Stenman U. H., National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clinical Chemistry 2008 54 12 11 79
57. Molina R., Barak V., van Dalen A., Tumor markers in breast cancer-European Group on Tumor Markers recommendations. Tumour Biology 2005 26 6 281 293 (Pubitemid 41619458)
58. Filippi V., Malamitsi J., Vlachou F., Laspas F., Georgiou E., Prassopoulos V., Andreou J., The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nuclear Medicine Communications 2011 32 2 85 90 2-s2.0-78650935810 10.1097/MNM.0b013e328341c898
59. Evangelista L., Baretta Z., Vinante L., Cervino A. R., Gregianin M., Ghiotto C., Saladini G., Sotti G., Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. European Journal of Nuclear Medicine and Molecular Imaging 2011 38 2 293 301 2-s2.0-79551559469 10.1007/s00259-010-1626-7
60. Champion L., Brain E., Giraudet A.-L., Le Stanc E., Wartski M., Edeline V., Madar O., Bellet D., Pecking A., Alberini J.-L., Breast cancer recurrence diagnosis suspected on tumor marker rising. Cancer 2011 117 8 1621 1629 2-s2.0-79953768774 10.1002/cncr.25727
61. Grassetto G., Fornasiero A., Otello D., Bonciarelli G., Rossi E., Nashimben O., Minicozzi A. M., Crepaldi G., Pasini F., Facci E., Mandoliti G., Marzola M. C., Al-Nahhas A., Rubello D., 18F-FDG-PET/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: a multicentre study. European Journal of Radiology 2011 80 3 828 833 2-s2.0-80755148777 10.1016/j.ejrad.2010.04.029
62. Katayama T., Kubota K., Machida Y., Toriihara A., Shibuya H., Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers. Annals of Nuclear Medicine 2012 26 5 426 435 2-s2.0-84859053655 10.1007/s12149-012-0595-2
63. Sturgeon C. M., Lai L. C., Duffy M. J., Serum tumour markers: how to order and interpret them. BMJ 2009 339 7725 852 858 2-s2.0-70349859837 10.1136/bmj.b3527
64. Brooks M., Breast cancer screening and biomarkers. Methods in Molecular Biology 2009 472 307 321 2-s2.0-58149471243 10.1007/978-1-60327-492-0-13
65. Del Turco M. R., Palli D., Cariddi A., Ciatto S., Pacini P., Distante V., Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. Journal of the American Medical Association 1994 271 20 1593 1597 2-s2.0-0028308180 10.1001/jama.271.20.1593 (Pubitemid 24155619)
66. Liberati A., Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. Journal of the American Medical Association 1994 271 20 1587 1592 2-s2.0-0005247227 10.1001/jama.271.20.1587 (Pubitemid 24155618)
67. Cardoso F., Costa A., Norton L., Cameron D., Cufer T., Fallowfield L., Francis P., Gligorov J., Kyriakides S., Lin N., Pagani O., Senkus E., Thomssen C., Aapro M., Bergh J., Di Leo A., El Saghir N., Ganz P. A., Gelmon K., Goldhirsch A., Harbeck N., Houssami N., Hudis C., Kaufman B., Leadbeater M., Mayer M., Rodger A., Rugo H., Sacchini V., Sledge G., van't Veer L., Viale G., Krop I., Winer E., 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012 21 3 242 252 2-s2.0-84858118006 10.1016/j.breast. 2012.03.003
68. Hayward J. L., Rubens R. D., Carbone P. P., Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. British Journal of Cancer 1977 35 3 292 298 2-s2.0-0017348988 (Pubitemid 8057360)
69. Robertson J. F. R., Jaeger W., Syzmendera J. J., Selby C., Coleman R., Howell A., Winstanley J., Jonssen P. E., Bombardieri E., Sainsbury J. R. C., Gronberg H., Kumpulainen E., Blamey R. W., The objective measurement of remission and progression in metastatic breast cancer by use of serum tumor markers. European Journal of Cancer 1999 35 1 47 53 2-s2.0-0032991137 10.1016/S0959-8049(98)00297-4 (Pubitemid 29079490)
70. Kurebayashi J., Nishimura R., Tanaka K., Kohno N., Kurosumi M., Moriya T., Ogawa Y., Taguchi T., Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer 2004 11 4 389 395 2-s2.0-21644474494 10.1007/BF02968047
71. Melichar B., Biomarkers in the treatment of cancer: opportunities and pitfalls. Clinical Chemistry and Laboratory Medicine 2013 24 1 5
72. Lin N. U., Thomssen C., Cardoso F., International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 2013 22 3 203 210
73. Evangelista L., Cervino A. R., Ghiotto C., Al-Nahhas A., Rubello D., Muzzio P. C., Tumor marker-guided PET in breast cancer patients: a recipe for a perfect wedding: a systematic literature review and meta-analysis. Clinical Nuclear Medicine 2012 37 5 467 474 2-s2.0-84859642241 10.1097/RLU. 0b013e31824850b0
74. Madhavan D., Cuk K., Burwinkel B., Yang R., Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Frontiers in Genetics 2013 21 4, article 116
75. Cuk K., Zucknick M., Heil J., Madhavan D., Schott S., Turchinovich A., Arlt D., Rath M., Sohn C., Benner A., Junkermann H., Schneeweiss A., Burwinkel B., Circulating microRNAs in plasma as early detection markers for breast cancer. International Journal of Cancer 2013 132 7 1602 1612
76. Zhao H., Shen J., Medico L., Wang D., Ambrosone C. B., Liu S., A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE 2010 5 10 2-s2.0-78149433644 10.1371/journal.pone.0013735 e13735
77. Chan M., Liaw C. S., Ji S. M., Tan H. H., Wong C. Y., Thike A. A., Tan P. H., Ho G. H., Lee A. S., Identification of circulating MicroRNA signatures for breast cancer detection. Clinical Cancer Research 2013 19 16 4477 4487
78. Leidner R. S., Li L., Thompson C. L., Dampening enthusiasm for circulating microRNA in breast cancer. PLoS ONE 2013 8 3 e57841